Airway Inflammation Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Background:
- Individuals who have severe asthma that is not easily controlled by current treatments are
in need of new treatments to prevent potentially life-threatening asthma attacks.
Experiments in mice have found that a medication called pioglitazone hydrochloride (Actos ),
which is used to treat patients with diabetes, may be effective for treating severe asthma.
Researchers are interested in determining whether Actos is effective in improving the
quality of life in subjects with severe asthma who continue to have symptoms despite maximum
standard medical therapy.
Objectives:
- To assess the effectiveness of pioglitazone hydrochloride as a treatment for patients with
severe asthma that is not controlled by standard treatments.
Eligibility:
- Individuals between 18 and 75 years of age who have been diagnosed with and treated for
severe asthma for at least 1 year.
Design:
- Potential participants will have a screening visit to determine eligibility for the
study. The visit will involve breathing tests, chest x rays, heart and lung monitoring,
and blood tests.
- Eligible participants will have a full medical history and will answer a series of
questionnaires about their quality of life with asthma.
- Phase 1: Patients will record lung function and asthma symptoms morning and evening for
4 weeks. At the end of this period, patients will be evaluated with breathing, allergy,
and blood tests, as well as questionnaires. Patients will also provide a sputum sample.
- Phase 2: Patients will receive regular doses of either pioglitazone hydrochloride or a
placebo for 16 weeks. Patients will return to the National Institutes of Health every 4
weeks for tests.
- Phase 3: Wash-out period without study drugs for 4 weeks, similar to Phase 1.
- Phase 4: Patients will receive regular doses of either pioglitazone hydrochloride or a
placebo for 16 weeks. Patients who received placebo will be given the study drug, and
vice versa. Patients will return to the National Institutes of Health every 4 weeks for
tests.
- Phase 5: Medications will be stopped, and patients will return to the National
Institutes of Health 4 weeks later for final tests.
New therapies are needed for patients with asthma who are sub-optimally controlled by standard measures. Pioglitazone hydrochloride (Actos ) is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-Gamma (PPAR Gamma). Studies in murine models of allergic asthma have shown that PPAR Gamma agonists down-regulate allergen-mediated airway inflammation and airway hyperresponsiveness. This protocol is a randomized, placebo-controlled, doubleblind, crossover (phase II) pilot study of the efficacy of pioglitazone for the treatment of patients with severe, refractory asthma. The primary end-point for this study will be quality of life as determined by the Asthma Quality of Life Questionnaire (AQLQ) score. Secondary end-points will include indices of airway inflammation, airflow obstruction, airway hyperreactivity, and asthma symptoms. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04885738 -
The Value of FeNO in Predicting Airway Eosinophilic Inflammation
|
||
Recruiting |
NCT02767973 -
To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility
|
N/A | |
Completed |
NCT00814281 -
Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?
|
N/A | |
Completed |
NCT03861390 -
Woodsmoke Particulate + Prednisone
|
Phase 1/Phase 2 | |
Completed |
NCT00869596 -
Study of Biomarkers of Airway Inflammation (0000-128)
|
Phase 1 | |
Completed |
NCT00455377 -
Lung Function and Airway Inflammation in Portland Cement Workers
|
N/A | |
Completed |
NCT00527345 -
Children's Exposures/Health Effects/Diesel Exhaust
|
N/A | |
Completed |
NCT03444298 -
A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults
|
Phase 2 | |
Withdrawn |
NCT00604578 -
Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma
|
Phase 2 | |
Completed |
NCT00989365 -
Effect of Aerobic Training on Asthmatic Patients
|
N/A | |
Completed |
NCT00673907 -
HIPWOODS - Health Effects Related to Exposure to Particle Pollution From Woodburning Stoves
|
N/A | |
Completed |
NCT00635882 -
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
|
Phase 2 | |
Enrolling by invitation |
NCT03851406 -
Woodsmoke Particulate + Hypertonic Saline
|
N/A | |
Completed |
NCT03924635 -
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
|
Phase 4 | |
Completed |
NCT00727714 -
Lung Function and Inflammatory Markers in Cement Dust Exposed Workers: A Cross-shifts Study
|
N/A |